Phaseline

Targets › GABA

GABA: drug programs, companies and trials

6 programs from 6 companies in 7 trials: 3 Phase 3, 2 Phase 2, 1 Phase 1, 1 Phase 4; Psychiatry, Neurology, Other; next expected readout Jun 2027.

Open in Phaseline: the race on GABA, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Sherief Abd-ElsalamGABA (Gamma amino butyric acid)
GABA receptor agonist
GABAPhase 4EpilepsyDec 2028
Neurona TherapeuticsNRTX-1001
GABA-secreting GABAergic interneurons derived from human embryonic stem cells
GABAPhase 3Mesial Temporal Lobe Epilepsy; Epilepsy, Temporal LobeJun 2027
PleoPharmaPP-01
Cannabinoid-1 (CB1) partial agonist / GABAergic modulator
CNR1, GABAPhase 3Cannabis WithdrawalJun 2027
Beth Israel Deaconess Medical CenterTiagabine
GABA reuptake inhibitor
GABAPhase 3Schizophrenia–
Aelis FarmaAEF0217
GABA-positive allosteric modulator (GABAergic steroid)
GABAPhase 2Down Syndrome (Trisomy 21)Dec 2027
University of California, San DiegoPhentermine-Topiramate
Sympathomimetic amine and gamma-aminobutyric acid modulator for weight loss
HTR2C, GABAPhase 2Colitis, Ulcerative–

Conditions

Schizophrenia (1) Cannabis Withdrawal (1) Mesial Temporal Lobe Epilepsy (1) Epilepsy, Temporal Lobe (1) Epilepsy (1) Down Syndrome (Trisomy 21) (1) Colitis, Ulcerative (1)

Modalities

small molecule (5), protein or peptide (1)

Companies

Beth Israel Deaconess Medical Center (1) PleoPharma (1) Neurona Therapeutics (1) Sherief Abd-Elsalam (1) Aelis Farma (1) University of California, San Diego (1)

Related targets

CNR1 (1) HTR2C (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.